IDEAS home Printed from https://ideas.repec.org/a/eee/socmed/v75y2012i12p2353-2361.html
   My bibliography  Save this article

The debate about the funding of Herceptin: A case study of ‘countervailing powers’

Author

Listed:
  • Gabe, Jonathan
  • Chamberlain, Kerry
  • Norris, Pauline
  • Dew, Kevin
  • Madden, Helen
  • Hodgetts, Darrin

Abstract

In December 2008 the newly elected Prime Minister of New Zealand bypassed the agency that negotiates with manufacturers about the cost of medicines and agreed to fund Herceptin for women with early stage breast cancer for a twelve months course of treatment. This paper describes the unfolding of this decision and seeks to explain it in terms of the theory of countervailing powers, which has recently been applied to understand the rapid growth of medicines and the governance of the pharmaceutical industry. We explore the role of various actors in this debate about Herceptin funding, drawing on documentary analysis based on a systematic search of journals, websites and media databases. The case of Herceptin both confirms and questions the propositions of countervailing powers theory. On the one hand the manufacturers of the drug proved to be highly influential in their attempts to get Herceptin funded and were generally supported by consumer groups. On the other hand some scientists and regulators attempted to challenge the power of the manufacturers, with the regulators not showing signs of corporate bias as one might expect. Groups did not, as has been proposed, exert power monolithically, with several groups exhibiting opposing factions. The media, ignored in this literature, are considered as a potential countervailing force in the debate. In the end the government bypassed the recommendation of its regulators, thereby undermining the latter's efforts to act as a countervailing power.

Suggested Citation

  • Gabe, Jonathan & Chamberlain, Kerry & Norris, Pauline & Dew, Kevin & Madden, Helen & Hodgetts, Darrin, 2012. "The debate about the funding of Herceptin: A case study of ‘countervailing powers’," Social Science & Medicine, Elsevier, vol. 75(12), pages 2353-2361.
    • Handle: RePEc:eee:socmed:v:75:y:2012:i:12:p:2353-2361
    DOI: 10.1016/j.socscimed.2012.09.009
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0277953612006727
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.socscimed.2012.09.009?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Hedgecoe, Adam, 2005. "'At the point at which you can do something about it, then it becomes more relevant': Informed consent in the pharmacogenetic clinic," Social Science & Medicine, Elsevier, vol. 61(6), pages 1201-1210, September.
    2. Gary Schwitzer, 2008. "How Do US Journalists Cover Treatments, Tests, Products, and Procedures? An Evaluation of 500 Stories," PLOS Medicine, Public Library of Science, vol. 5(5), pages 1-5, May.
    3. Benelli, Eva, 2003. "The role of the media in steering public opinion on healthcare issues," Health Policy, Elsevier, vol. 63(2), pages 179-186, February.
    4. Busfield, Joan, 2010. "'A pill for every ill': Explaining the expansion in medicine use," Social Science & Medicine, Elsevier, vol. 70(6), pages 934-941, March.
    5. Sismondo, Sergio, 2008. "How pharmaceutical industry funding affects trial outcomes: Causal structures and responses," Social Science & Medicine, Elsevier, vol. 66(9), pages 1909-1914, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Vallée, Manuel, 2019. "The countervailing forces behind France's low Ritalin consumption," Social Science & Medicine, Elsevier, vol. 238(C), pages 1-1.
    2. Davis, Courtney, 2015. "Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?," Social Science & Medicine, Elsevier, vol. 131(C), pages 207-214.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Unruh, Lynn & Rice, Thomas & Rosenau, Pauline Vaillancourt & Barnes, Andrew J., 2016. "The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?," Health Policy, Elsevier, vol. 120(7), pages 797-808.
    2. S Scott Graham & Zoltan P Majdik & Dave Clark & Molly M Kessler & Tristin Brynn Hooker, 2020. "Relationships among commercial practices and author conflicts of interest in biomedical publishing," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-11, July.
    3. Gérard Mondello, 2020. "Building Belief Systems and Medical Ethics: The Covid-19 Controversies," GREDEG Working Papers 2020-35, Groupe de REcherche en Droit, Economie, Gestion (GREDEG CNRS), Université Côte d'Azur, France.
    4. Padamsee, Tasleem Juana, 2011. "The pharmaceutical corporation and the 'good work' of managing women's bodies," Social Science & Medicine, Elsevier, vol. 72(8), pages 1342-1350, April.
    5. Elise M. R. Smith & Stephen Molldrem & Jeffrey S. Farroni & Emma Tumilty, 2024. "Articulating the social responsibilities of translational science," Palgrave Communications, Palgrave Macmillan, vol. 11(1), pages 1-13, December.
    6. Bell, Susan E. & Figert, Anne E., 2012. "Medicalization and pharmaceuticalization at the intersections: Looking backward, sideways and forward," Social Science & Medicine, Elsevier, vol. 75(5), pages 775-783.
    7. Ebeling, Mary, 2011. "'Get with the Program!': Pharmaceutical marketing, symptom checklists and self-diagnosis," Social Science & Medicine, Elsevier, vol. 73(6), pages 825-832, September.
    8. Benedikt Fecher & Freia Kuper & Birte Fähnrich & Hannah Schmid-Petri & Thomas Schildhauer & Peter Weingart & Holger Wormer, 2023. "Balancing interests between freedom and censorship: Organizational strategies for quality assurance in science communication," Science and Public Policy, Oxford University Press, vol. 50(1), pages 1-14.
    9. Miller, Fiona Alice & Ahern, Catherine & Smith, Christopher A. & Harvey, Erin A., 2006. "Understanding the new human genetics: A review of scientific editorials," Social Science & Medicine, Elsevier, vol. 62(10), pages 2373-2385, May.
    10. Joseph W Taylor & Marie Long & Elizabeth Ashley & Alex Denning & Beatrice Gout & Kayleigh Hansen & Thomas Huws & Leifa Jennings & Sinead Quinn & Patrick Sarkies & Alex Wojtowicz & Philip M Newton, 2015. "When Medical News Comes from Press Releases—A Case Study of Pancreatic Cancer and Processed Meat," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-13, June.
    11. Amanda Wilson & Billie Bonevski & Alison Jones & David Henry, 2009. "Media Reporting of Health Interventions: Signs of Improvement, but Major Problems Persist," PLOS ONE, Public Library of Science, vol. 4(3), pages 1-5, March.
    12. Thomas, Felicity, 2016. "Young people's use of medicines: Pharmaceuticalised governance and illness management within household and school settings," Social Science & Medicine, Elsevier, vol. 165(C), pages 150-158.
    13. Collins, Patricia A. & Abelson, Julia & Pyman, Heather & Lavis, John N., 2006. "Are we expecting too much from print media? An analysis of newspaper coverage of the 2002 Canadian healthcare reform debate," Social Science & Medicine, Elsevier, vol. 63(1), pages 89-102, July.
    14. Joaquin Chapa & Zeeshan Haq & Adam S. Cifu, 2017. "Comparative analysis of the factors associated with citation and media coverage of clinical research," Scientometrics, Springer;Akadémiai Kiadó, vol. 112(3), pages 1271-1283, September.
    15. Fisher, Jill A. & Cottingham, Marci D. & Kalbaugh, Corey A., 2015. "Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities," Social Science & Medicine, Elsevier, vol. 131(C), pages 322-330.
    16. Tatiana Breder Emerich & Aline Guio Cavaca & Edson Theodoro Santos-Neto & Victor Israel Gentilli & Adauto Emmerich Oliveira, 2017. "Media Valuations of Health Journalism and Health Dynamics in Brazilian Printed Media," International Journal of Social Science Studies, Redfame publishing, vol. 5(1), pages 31-42, January.
    17. Michelle Nelson & Jiwoo Park, 2015. "Publicity as Covert Marketing? The Role of Persuasion Knowledge and Ethical Perceptions on Beliefs and Credibility in a Video News Release Story," Journal of Business Ethics, Springer, vol. 130(2), pages 327-341, August.
    18. Baum, Frances E. & Laris, Paul & Fisher, Matthew & Newman, Lareen & MacDougall, Colin, 2013. "“Never mind the logic, give me the numbers”: Former Australian health ministers' perspectives on the social determinants of health," Social Science & Medicine, Elsevier, vol. 87(C), pages 138-146.
    19. Luca Iaboli & Luana Caselli & Angelina Filice & Gianpaolo Russi & Eleonora Belletti, 2010. "The Unbearable Lightness of Health Science Reporting: A Week Examining Italian Print Media," PLOS ONE, Public Library of Science, vol. 5(3), pages 1-6, March.
    20. Daw, Jamie R. & Morgan, Steven G. & Thomson, Paige A. & Law, Michael R., 2013. "Here today, gone tomorrow: The issue attention cycle and national print media coverage of prescription drug financing in Canada," Health Policy, Elsevier, vol. 110(1), pages 67-75.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:75:y:2012:i:12:p:2353-2361. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.